← Back to Clinical Trials
Recruiting NCT06982716

NCT06982716 Evaluating the Clinical Effectiveness of a Community-based Hearing Aid Fitting Service Delivery Model Facilitated by Community Healthcare Workers (CHWs) Providing Smartphone-based In-situ and Pre-set Hearing Aid Fittings in Low- and Middle-income Communities (LMICs)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06982716
Status Recruiting
Phase
Sponsor University of Pretoria
Condition Hearing Loss
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-05-21
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Lexie Lumen Hearing AidsGo Ultra Hearing Aids

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-05-21 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to advance hearing care in low- and middle-income countries (LMICs) through the rigorous evaluation and optimization of innovative interventions and technologies. This study encompasses the following key aim: This study aims to establish the effectiveness of community-based hearing aid fittings facilitated by community healthcare workers (CHWs) using mobile health (mHealth) technologies in low- and middle-income communities (LMICs). The primary goal is to determine the efficacy of CHW-facilitated smartphone-based in-situ hearing aid (HA) fittings (a proprietary fitting based on the NAL-NL2 algorithm) and pre-set HAs fittings compared to minimal amplification through a single-blind randomized controlled trial (RCT). By comparing self-reported benefits between the experimental and control groups, this aim seeks to demonstrate the superiority of the CHW-facilitated smartphone-based and pre-set hearing aid fittings compared to minimal amplification.

Eligibility Criteria

Inclusion Criteria: * 18 years and older * Confirmed mild to severe (20 to \< 80 dB PTA in both ears; (World Health Organization, 2021)) hearing loss (determined during baseline assessments) * Willing/available to commit to at least 6- and 12-week follow-ups Exclusion Criteria: * Younger than 18 years * Hearing loss too severe (≥80 dB HL PTA) * Normal hearing (\<20 dB HL PTA) * Middle ear pathology such as otitis media; active drainage from the ears. * Unwilling/unavailable to commit to at least 6- and 12-week follow-ups. * Unilateral hearing loss

Contact & Investigator

Central Contact

Caitlin Frisby, PhD Audiology

✉ caitlin.frisby@up.ac.za

📞 +27 78 300 2511

Principal Investigator

Professor De Wet Swanepoel, PhD Audiology

PRINCIPAL INVESTIGATOR

University of Pretoria

Frequently Asked Questions

Who can join the NCT06982716 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hearing Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06982716 currently recruiting?

Yes, NCT06982716 is actively recruiting participants. Contact the research team at caitlin.frisby@up.ac.za for enrollment information.

Where is the NCT06982716 trial being conducted?

This trial is being conducted at Pretoria, South Africa, Cape Town, South Africa, Paarl, South Africa.

Who is sponsoring the NCT06982716 clinical trial?

NCT06982716 is sponsored by University of Pretoria. The principal investigator is Professor De Wet Swanepoel, PhD Audiology at University of Pretoria. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology